共查询到20条相似文献,搜索用时 11 毫秒
1.
2.
Furio Zucco MD Roberta Ciampichini MSc Angelo Lavano MD Amedeo Costantini MD Marisa De Rose MD Paolo Poli MD Gianpaolo Fortini MD Laura Demartini MD Enrico De Simone MD Valentino Menardo MD Piero Cisotto MD Mario Meglio MD Luciana Scalone PhD Lorenzo G. Mantovani DSc 《Neuromodulation》2015,18(4):266-276
3.
4.
Cost‐Effectiveness Modeling of Repetitive Transcranial Magnetic Stimulation Compared to Electroconvulsive Therapy for Treatment‐Resistant Depression in Singapore 下载免费PDF全文
Ying Jiao Zhao PhD Ai Leng Khoo PhD Monica Teng MHSc Boon Peng Lim B Yee Ming Mok MMed Grad Dip 《Neuromodulation》2018,21(4):376-382
5.
6.
7.
K. Malmivaara J.
hman R. Kivisaari J. Hernesniemi J. Siironen 《European journal of neurology》2011,18(3):402-409
Background: Decompressive craniectomy is used regularly in traumatic brain injury (TBI) and malignant middle cerebral artery infarction. Its benefits for other causes of non‐traumatic brain swelling, if any, are unclear, especially after a devastating primary event. Methods: We evaluated the outcomes as well as treatment costs of all emergency decompressive craniectomies performed between the 2000 and 2006 in a single institution to lower intractable intracranial pressure, excluding the standard indications TBI and malignant middle cerebral infarction. The health‐related quality of life (HRQoL) was evaluated on the Euroqol (EQ‐5D) scale, and cost of a quality‐adjusted life year (QALY) calculated. Results: The overall 3‐year mortality rate was 62% for subarachnoid haemorrhage (SAH, 29 patients) and 31% for other neurological emergencies (13 patients). Patients with SAH were on average 13 years older than the other indications mean. Of the non‐survivors, 45% died within a month and 95% within 1 year. Median EQ‐5D index values were poor (0.15 for SAH and 0.62 for the other emergencies, versus 0.85 for the normal population), but of the survivors, 73% and 89% were able to live at home. The cost of neurosurgical treatment for one QALY was 11 000 € for SAH and 2000 € for other emergencies. Conclusion: Mortality after non‐traumatic neurological emergencies leading to decompressive craniectomy was high, and the HRQoL index of the survivors was poor. Most survivors were, however, able to live at home, and the cost of neurosurgical treatment for a QALY gained was acceptable. 相似文献
8.
9.
10.
Anthony A. Menditto Charles J. Wallace Robert P. Liberman Jillon Vander Wal Nicole Tuomi Jones Paul Stuve 《American journal of psychiatric rehabilitation》2013,16(2):200-219
Abstract Functional assessment of persons with psychiatric disabilities requires reliable and valid instruments that can be used by clinicians for planning psychosocial rehabilitation services. Two such instruments, the Independent Living Skills Inventory and the Independent Living Skills Survey are operationalized and behaviorally specific tools that can be administered as questionnaires or interviews. Both instruments have well-documented reliability and validity and are ‘user-friendly.” 相似文献
11.
K. Malmivaara R. Kivisaari J. Hernesniemi J. Siironen 《European journal of neurology》2011,18(4):656-662
Background and purpose: Decompressive craniectomy (DC) is used regularly in traumatic brain injury (TBI). There are, however, no cost‐effectiveness studies of the procedure. Methods: We evaluated the outcomes and treatment costs of all decompressive craniectomies performed between the 2000 and 2006 in a single institution to lower intractable intracranial pressure after TBI. The health‐related quality of life was evaluated on the Euroqol (EQ‐5D) questionnaire and on the visual‐analogue scale (VAS), and cost of a quality‐adjusted life year (QALY) was calculated. Results: In this study of 54 patients, the median follow‐up time was 5.6 years. Overall mortality rate was 41%. Of the 22 non‐survivors, 73% died within 30 days. For 32 survivors, the median EQ‐5D index value was 0.85, which is equal to the normal population. The median VAS value was 73, whilst normal population’s value is 80. Of the survivors, 81% (26/32) were able to live at home and 31% (10/32) returned to work. The cost of neurosurgical treatment for one QALY was 2400€. Estimation for all medical costs, including rehabilitation and anticipated future costs, resulted cost of a QALY 17 900 €. Conclusion Mortality after severe TBI leading to DC was high, but amongst the survivors, the health‐related quality of life was equal to normal population. Most survivors were able to live at home and were almost as satisfied with their health as in general people are. Cost of neurosurgical treatment was low, and also including all evaluated costs, cost of a QALY gained was acceptable. 相似文献
12.
13.
Cost‐effectiveness of neurostimulation in Parkinson's disease with early motor complications 下载免费PDF全文
Judith Dams PhD Monika Balzer‐Geldsetzer PhD Uwe Siebert MD MPH MSc ScD Günther Deuschl MD W.M. Michael Schuepbach MD Paul Krack MD PhD Lars Timmermann MD PhD Alfons Schnitzler MD PhD Jens‐Peter Reese PhD MPH Richard Dodel MD MPH for the EARLYSTIM‐investigators 《Movement disorders》2016,31(8):1183-1191
14.
15.
Judith Dams MSc Uwe Siebert MD MPH MSc ScD Bernhard Bornschein MD MPH Jens Volkmann MD Günther Deuschl MD Wolfgang H. Oertel MD Richard Dodel MD MPH Jens‐Peter Reese PhD MPH 《Movement disorders》2013,28(6):763-771
In addition to medical treatment, deep brain stimulation has become an alternative therapeutic option in advanced Parkinson's disease. High initial costs of surgery have to be weighted against long‐term gains in health‐related quality of life. The objective of this study was to assess the cost‐effectiveness of deep brain stimulation compared with long‐term medical treatment. We performed a cost‐utility analysis using a lifetime Markov model for Parkinson's disease. Health utilities were evaluated using the EQ‐5D generic health status measure. Data on effectiveness and adverse events were obtained from clinical studies, published reports, or meta‐analyses. Costs were assessed from the German health care provider perspective. Both were discounted at 3% per year. Key assumptions affecting costs and health status were investigated using one‐way and two‐way sensitivity analyses. The lifetime incremental cost‐utility ratio for deep brain stimulation was €6700 per quality‐adjusted life year (QALY) and €9800 and €2500 per United Parkinson's Disease Rating Scale part II (motor experiences of daily living) and part III (motor examination) score point gained, respectively. Deep brain stimulation costs were mainly driven by the cost of surgery and of battery exchange. Health status was improved and motor complications were reduced by DBS. Sensitivity analysis revealed that battery life time was the most influential parameter, with the incremental cost‐utility ratio ranging from €20,000 per QALY to deep brain stimulation dominating medical treatment. Deep brain stimulation can be considered cost‐effective, offering a value‐for‐money profile comparable to other well accepted health care technologies. Our data support adopting and reimbursing deep brain stimulation within the German health care system. © 2013 Movement Disorder Society 相似文献
16.
17.
18.
W. Quentin S. G. Riedel‐Heller M. Luppa A. Rudolph H.‐H. König 《Acta psychiatrica Scandinavica》2010,121(4):243-259
Quentin W, Riedel‐Heller SG, Luppa M, Rudolph A, König H‐H. Cost‐of‐illness studies of dementia: a systematic review focusing on stage dependency of costs. Objective: To review cost‐of‐illness (COI) studies of dementia from Europe and North America which report costs per patient by disease stage. Method: A systematic literature search was performed in electronic databases. Studies were classified according to important determinants of costs. Results were converted into year 2006 USD‐PPP, and summarized as costs for formal and informal care in mild, moderate and severe dementia. Results: 28 studies were evaluated. They used a wide range of methods. Costs more than doubled from mild to severe dementia. Patterns and size of estimated costs depended primarily on study objectives (estimation of total costs–net costs), living arrangements of patients (community‐dwelling–institutionalized) and inclusion of informal care. Conclusion: This review is the first to have focused on costs in different stages of dementia. The stage is an important determinant of costs. However, characteristics of individual studies need to be considered, when making use of their results. 相似文献
19.
20.
Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial) 下载免费PDF全文
Martin Knapp Derek King Renée Romeo Jessica Adams Ashley Baldwin Clive Ballard Sube Banerjee Robert Barber Peter Bentham Richard G Brown Alistair Burns Tom Dening David Findlay Clive Holmes Tony Johnson Cornelius Katona James Lindesay Ajay Macharouthu Ian McKeith Rupert McShane John T O'Brien Patrick P J Phillips Bart Sheehan Robert Howard 《International journal of geriatric psychiatry》2017,32(12):1205-1216